Barclays’s Five Prime Therapeutics, Inc. FPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q2 | – | Sell |
-136,346
| Closed | -$5.14M | – | 5207 |
|
|
2021
Q1 | $5.14M | Buy |
136,346
+124,808
| +1,082% | +$3.11M | ﹤0.01% | 1498 |
|
|
2020
Q4 | $196K | Sell |
11,538
-195,665
| -94% | -$2.45M | ﹤0.01% | 3771 |
|
|
2020
Q3 | $973K | Buy |
207,203
+187,945
| +976% | +$955K | ﹤0.01% | 2719 |
|
|
2020
Q2 | $117K | Sell |
19,258
-2,616
| -12% | -$10.8K | ﹤0.01% | 4415 |
|
|
2020
Q1 | $50K | Sell |
21,874
-23,659
| -52% | -$100K | ﹤0.01% | 5242 |
|
|
2019
Q4 | $209K | Buy |
45,533
+14,287
| +46% | +$56.6K | ﹤0.01% | 5001 |
|
|
2019
Q3 | $121K | Sell |
31,246
-2,207
| -7% | -$12.1K | ﹤0.01% | 5339 |
|
|
2019
Q2 | $201K | Buy |
33,453
+11,526
| +53% | +$110K | ﹤0.01% | 5106 |
|
|
2019
Q1 | $294K | Buy |
21,927
+6,079
| +38% | +$69.3K | ﹤0.01% | 4539 |
|
|
2018
Q4 | $147K | Sell |
15,848
-22,506
| -59% | -$268K | ﹤0.01% | 4788 |
|
|
2018
Q3 | $534K | Buy |
38,354
+33,584
| +704% | +$499K | ﹤0.01% | 4217 |
|
|
2018
Q2 | $75K | Sell |
4,770
-20,677
| -81% | -$361K | ﹤0.01% | 5425 |
|
|
2018
Q1 | $437K | Buy |
25,447
+18,414
| +262% | +$359K | ﹤0.01% | 4106 |
|
|
2017
Q4 | $154K | Sell |
7,033
-3,082
| -30% | -$99.1K | ﹤0.01% | 4906 |
|
|
2017
Q3 | $413K | Buy |
10,115
+866
| +9% | +$27.2K | ﹤0.01% | 3795 |
|
|
2017
Q2 | $278K | Sell |
9,249
-6,295
| -40% | -$196K | ﹤0.01% | 4082 |
|
|
2017
Q1 | $562K | Buy |
15,544
+7,854
| +102% | +$346K | ﹤0.01% | 3288 |
|
|
2016
Q4 | $385K | Buy |
7,690
+2,718
| +55% | +$143K | ﹤0.01% | 3624 |
|
|
2016
Q3 | $261K | Buy |
4,972
+2,794
| +128% | +$133K | ﹤0.01% | 3737 |
|
|
2016
Q2 | $91K | Sell |
2,178
-65,869
| -97% | -$2.87M | ﹤0.01% | 4468 |
|
|
2016
Q1 | $2.72M | Buy |
68,047
+25,425
| +60% | +$874K | ﹤0.01% | 1663 |
|
|
2015
Q4 | $1.75M | Buy |
42,622
+31,174
| +272% | +$1.05M | ﹤0.01% | 2124 |
|
|
2015
Q3 | $172K | Buy |
11,448
+6,551
| +134% | +$141K | ﹤0.01% | 4244 |
|
|
2015
Q2 | $118K | Buy |
4,897
+3,895
| +389% | +$86.8K | ﹤0.01% | 4553 |
|
|
2015
Q1 | $23K | Buy |
1,002
+20
| +2% | +$505 | ﹤0.01% | 5764 |
|
|
2014
Q4 | $27K | Buy |
982
+416
| +73% | +$7.16K | ﹤0.01% | 6144 |
|
|
2014
Q3 | $6K | Buy |
566
+229
| +68% | +$2.89K | ﹤0.01% | 7137 |
|
|
2014
Q2 | $5K | Sell |
337
-38
| -10% | -$545 | ﹤0.01% | 7141 |
|
|
2014
Q1 | $7K | Buy |
375
+284
| +312% | +$4.82K | ﹤0.01% | 7094 |
|
|
2013
Q4 | $1K | Buy |
+91
| New | +$1.13K | ﹤0.01% | 7466 |
|
Barclays's FPRX Position: Q2 2021 in Review
Barclays sold out of Five Prime Therapeutics, Inc. (FPRX) in Q2 2021, closing a stake of 136,346 shares — an estimated $5.14M sold.
Barclays first reported a position in FPRX in Q4 2013 and held it in 30 quarters. The position peaked at $5.14M in Q1 2021. 0 funds tracked by Wall St. Rank hold FPRX as of Q2 2021.
- Barclays reported no remaining Five Prime Therapeutics, Inc. position as of Q2 2021 after selling out during the quarter.
- Barclays sold 136,346 Five Prime Therapeutics, Inc. shares in Q2 2021, an estimated $5.14M.
- Barclays first reported a position in Five Prime Therapeutics, Inc. in Q4 2013 and held it in 30 quarters.
- Barclays's Five Prime Therapeutics, Inc. position peaked at $5.14M in Q1 2021.
- 0 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q2 2021.
Based on Barclays's 13F filing for Q2 2021, filed 13 Aug 2021.